Brought to you by 
Taris Biomedical brings in $12.5mm through its Series C venture round
12 Apr 2013
Executive Summary
Taris Biomedical Inc. (bladder disease treatments) has raised $12.5mm through what is believed to be its Series C venture round. Current shareholders Flagship Ventures, Flybridge Capital Partners, Polaris Partners, and Third Rock Ventures participated. The company will use the money to continue developing LiRIS (Lidocaine Releasing Intravesical System) for interstitial cystitis patients. Concurrent with the financing, Taris announced that it had dosed its first patient with LiRIS in a second Phase II study. The company has raised almost $50mm since its 2009 inception.
Deal Industry
- Medical Devices
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Site Specific
-
Drug Delivery
-
Medical Devices
- Implantable Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Taris Biomedical brings in $12.5mm through its Series C venture round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice